Therapeutic Strategies and Molecular Correlates in Aggressive B-cell Lymphomas

Division Of Clinical Sciences - Nci

Investigators

Linked publications & trials

Abstract

We have been working on 1) the validation of clinical and molecular indices of outcome with DA-EPOCH-R in DLBCL; 2) pathobiology and treatment of primary Mediastinal B-cell Lymphoma and Mediastinal Gray Zone Lymphoma; and 3) targeting NF-kB in translational studies of DLBCL. Accomplishments: We have shown circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. We found CD5-negative mantle cell lymphoma clinicopathologic features of an indolent variant that confers a survival advantage. I served on the Clinical Advisory Committee for the International Consensus Classification of Mature Lymphoid Neoplasms. We showed doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment. We provided a mechanistic understanding of the benefit of ibrutinib addition to chemotherapy, supporting its use in younger patients with non-GCB DLBCL. We collaborated with the City of Hope to conduct a gene therapy study using a decoy of the HIV TAT-reactive element in patients undergoing treatment of HIV-lymphoma. Our studies employing targeted drugs in DLBCL have direct relevance to the treatment of HIV-associated DLBCL including inhibition of BCR signaling. Recently we have developed studies for the treatment of EBV-associated lymphoproliferative disease that occur in the setting of immunodeficiency including HIV infection.